FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.

Abstract:

PURPOSE:To investigate the clinical impact of FDG-PET/CT for staging and treatment planning in high-risk primary breast cancer. METHODS:Women with high-risk primary breast cancer were enrolled between September 2017 and August 2019 at Odense University Hospital, Denmark. Conventional mammography with/without MRI was performed before staging by FDG-PET/CT. We studied the accuracy of FDG-PET/CT for the detection of distant metastases, the effect on the change of treatment, and the prevalence of incidental findings. Biopsy and follow-up were used as a reference standard for the accuracy analysis. RESULTS:Of 103 women, 24 (23%) were diagnosed with distant metastases by FDG-PET/CT. Among these, breast surgery was omitted in 18 and could have been spared in six. Another sixteen (16%) patients were upstaged to more advanced loco-regional disease, leading to more extensive radiotherapy. Sensitivity and specificity for diagnosing distant metastases were 1.00 (95% confidence interval: 0.86-1.00) and 0.95 (0.88-0.99), respectively. Twenty-nine incidental findings were detected in 24 women (23%), leading to further examinations in 22 and diagnosis of eight (8/22, 36%) synchronous diseases: cancer (n = 4), thyroiditis (n = 2), aorta aneurysm (n = 1), and meningioma (n = 1). CONCLUSIONS:FDG-PET/CT had a substantial impact on staging and change of treatment in women with high-risk primary breast cancer, and further examination of incidental findings was considered clinically relevant. Our findings suggest that FDG-PET/CT should be considered for primary staging in high-risk primary breast cancer to improve treatment planning.

authors

Vogsen M,Jensen JD,Christensen IY,Gerke O,Jylling AMB,Larsen LB,Braad PE,Søe KL,Bille C,Ewertz M,Hildebrandt MG

doi

10.1007/s10549-020-05929-3

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

145-153

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-020-05929-3

journal_volume

185

pub_type

杂志文章
  • Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

    abstract::Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction. Imatinib is a CYP3A4 inhibitor. A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased docetaxel clearance. Doce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1413-6

    authors: Connolly RM,Rudek MA,Garrett-Mayer E,Jeter SC,Donehower MG,Wright LA,Zhao M,Fetting JH,Emens LA,Stearns V,Davidson NE,Baker SD,Wolff AC

    更新日期:2011-05-01 00:00:00

  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

    abstract:PURPOSE:Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits exceptionally effectiv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05454-y

    authors: Wardell SE,Yllanes AP,Chao CA,Bae Y,Andreano KJ,Desautels TK,Heetderks KA,Blitzer JT,Norris JD,McDonnell DP

    更新日期:2020-01-01 00:00:00

  • The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40.

    abstract::Previous investigations into the relationship of CAG-repeat lengths in the androgen receptor (AR) gene to female breast cancer (BC) have yielded somewhat confusing results. Decreased AR transactivational activity lowers androgen:estrogen balance, and may thereby effect functional hyperestrogenicity. This may promote t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012942910375

    authors: Elhaji YA,Gottlieb B,Lumbroso R,Beitel LK,Foulkes WD,Pinsky L,Trifiro MA

    更新日期:2001-11-01 00:00:00

  • A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.

    abstract::Bone morphogenetic proteins (BMPs) regulate diverse cellular processes, such as proliferation, differentiation, and apoptosis. The BMPs have been studied in several cancers, but thus far contradictory results have been obtained and, especially in breast cancer, information on BMPs is still limited. We performed a syst...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9362-1

    authors: Alarmo EL,Kuukasjärvi T,Karhu R,Kallioniemi A

    更新日期:2007-06-01 00:00:00

  • Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

    abstract::Tumour hypoxia, being widespread in solid tumours, is related to an increased risk of invasion and metastasis as well as to resistance to chemotherapy and radiotherapy. Hypoxia-inducible factor-1alpha (HIF-1alpha) has emerged as the key regulator of the cellular response to hypoxia. In primary breast cancers, HIF-1alp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9589-5

    authors: Smollich M,Götte M,Kersting C,Fischgräbe J,Kiesel L,Wülfing P

    更新日期:2008-03-01 00:00:00

  • Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells.

    abstract::Hormone replacement therapy, which is a common menopausal treatment, is contraindicated in women with breast cancers due to concerns regarding the potential for breast cell proliferation. As such, there is a need for alternative methods for treating menopausal symptoms. To determine the influence of one such alternati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1020241509382

    authors: Bodinet C,Freudenstein J

    更新日期:2002-11-01 00:00:00

  • The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients.

    abstract::Several independent randomized controlled trials are initiated to investigate whether sentinel lymph node biopsy can be safely omitted in clinically node negative breast cancer patients with negative axillary ultrasound findings, who are treated with breast conserving therapy. A consequence of omitting sentinel lymph ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-013-2822-5

    authors: van Roozendaal LM,Schipper RJ,Van de Vijver KK,Haekens CM,Lobbes MB,Tjan-Heijnen VC,de Boer M,Smidt ML

    更新日期:2014-02-01 00:00:00

  • Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.

    abstract::The gene for Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (Pnck), a novel calmodulin kinase, is expressed in roughly one-third of human breast tumors, but not in adjoining normal tissues. Pnck alters EGFR stability and function, prompting this study to determine if Pnck expression has implications for HER-2...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3337-z

    authors: Deb TB,Zuo AH,Barndt RJ,Sengupta S,Jankovic R,Johnson MD

    更新日期:2015-04-01 00:00:00

  • Binding of lectins to human mammary tumors: ultrastructural study.

    abstract::The site of several lectin receptors in human mammary tumors and stroma was studied with the electron microscope. The advantage of the ultrastructural over light microscopic study was that lectin receptors could be localized with precision on the different cell types of the tumor and stroma. Eighteen human mammary car...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806482

    authors: Calafat J,Janssen H

    更新日期:1984-01-01 00:00:00

  • Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.

    abstract::The growth hormone and insulin-like growth factor (IGF) axis plays an essential role in the growth and development of the mammary gland. IGF1 and IGF1 receptor (IGF1R) may also play a role in the early transformation of mammary cells. Using a nested case-control design, the association between IGF1R expression in norm...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1313-1

    authors: Tamimi RM,Colditz GA,Wang Y,Collins LC,Hu R,Rosner B,Irie HY,Connolly JL,Schnitt SJ

    更新日期:2011-07-01 00:00:00

  • A longitudinal study of shoulder and arm morbidity in breast cancer survivors 7 years after sentinel lymph node biopsy or axillary lymph node dissection.

    abstract::Knowledge about long-term consequences of breast cancer treatment on shoulder and arm function and volume in stages I-II breast cancer survivors is limited. The effects of shoulder-arm function shortly after surgery on long-term function are unknown. One hundred and ninety-four women were examined pre-surgery (T0) and...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2509-y

    authors: Kootstra JJ,Dijkstra PU,Rietman H,de Vries J,Baas P,Geertzen JH,Hoekstra HJ,Hoekstra-Weebers JE

    更新日期:2013-05-01 00:00:00

  • Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.

    abstract:BACKGROUND:Paget's disease of the breast is an uncommon presentation of breast malignancy, accounting for 1-3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia. In the literature, differ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9880-5

    authors: Caliskan M,Gatti G,Sosnovskikh I,Rotmensz N,Botteri E,Musmeci S,Rosali dos Santos G,Viale G,Luini A

    更新日期:2008-12-01 00:00:00

  • Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.

    abstract:AIMS:Rapamycin and its analogues are currently being tested in clinical trials as novel-targeted anticancer agents. Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin. The aims of this study were to ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9746-x

    authors: Noh WC,Kim YH,Kim MS,Koh JS,Kim HA,Moon NM,Paik NS

    更新日期:2008-08-01 00:00:00

  • Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

    abstract:PURPOSE:In our microarray analysis we observed that Seven-in-Absentia Homolog 2 (SIAH2) levels were low in estrogen receptor (ER) positive breast tumors of patients resistant to first-line tamoxifen therapy. The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0125-z

    authors: Jansen MP,Ruigrok-Ritstier K,Dorssers LC,van Staveren IL,Look MP,Meijer-van Gelder ME,Sieuwerts AM,Helleman J,Sleijfer S,Klijn JG,Foekens JA,Berns EM

    更新日期:2009-07-01 00:00:00

  • Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.

    abstract:PURPOSE:We used multiplex immunofluorescence (mIF) to determine whether mitotic rate represents an independent prognostic marker in triple-negative breast cancer (TNBC). Secondary aims were to confirm the prognostic significance of immune cells in TNBC, and to investigate the relationship between immune cells and proli...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05396-5

    authors: Lai CPT,Yeong JPS,Tan AS,Ong CHC,Lee B,Lim JCT,Thike AA,Iqbal J,Dent RA,Lim EH,Tan PH

    更新日期:2019-11-01 00:00:00

  • The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk.

    abstract:PURPOSE:Vitamin D (VD) metabolism regulates adipose tissue, lipogenesis inflammation, and tumor growth. CYP24A1 is the key enzyme for metabolic inactivation of active VD (1,25(OH)2D3). We examined whether common germline single nucleotide polymorphisms (SNPs) in the CYP24A1 gene could affect the association between adu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05484-6

    authors: Cao S,Wei F,Zhou J,Zhu Z,Li W,Wu M

    更新日期:2020-01-01 00:00:00

  • Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies.

    abstract::Evidence for an association between fruit and vegetable intake and breast cancer risk is inconclusive. To clarify the association, we conducted a systematic review and meta-analysis of the evidence from prospective studies. We searched PubMed for prospective studies of fruit and vegetable intake and breast cancer risk...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2118-1

    authors: Aune D,Chan DS,Vieira AR,Rosenblatt DA,Vieira R,Greenwood DC,Norat T

    更新日期:2012-07-01 00:00:00

  • Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02).

    abstract:PURPOSE:To evaluate the loco-regional recurrence (LRR) rate after breast-conserving surgery without postoperative radiotherapy (RT) for ductal carcinoma in situ (DCIS) of the breast. METHODS:Between 2000 and 2010, 311 DCIS patients from 9 institutions were analyzed retrospectively. The median age was 47 (range, 20-82)...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-017-4111-1

    authors: Kim K,Jung SY,Shin KH,Kim JH,Han W,Lee HB,Huh SJ,Choi DH,Park W,Ahn SD,Kim SS,Kim JH,Suh CO,Kim YB,Kim IA,Kim S,Kim YJ

    更新日期:2017-02-01 00:00:00

  • ErbB-2 protein in sera and tumors of breast cancer patients.

    abstract::We compared levels of erbB-2 oncoprotein among three groups: Group I included 60 asymptomatic women; Group II had 51 women with benign breast biopsies; and Group III had 67 women with node-negative breast cancer. Serological levels of erbB-2 protein were measured in all participants; tumor levels were measured for Gro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006033214721

    authors: Breuer B,Smith S,Thor A,Edgerton S,Osborne MP,Minick R,Cody HS 3rd,Nowak E,Cortese A,Simmons RM,Carney WP,Brandt-Rauf PW

    更新日期:1998-06-01 00:00:00

  • High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.

    abstract:PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05543-3

    authors: Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

    更新日期:2020-04-01 00:00:00

  • Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.

    abstract:PURPOSE:Clinical trials demonstrated adjuvant aromatase inhibitor treatment is superior for decreasing breast cancer recurrence risk over adjuvant tamoxifen treatment as early as 2001. Yet clinical use for adjuvant treatment was not recommended by the American Society of Clinical Oncology until 2004. Aromatase inhibito...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9558-z

    authors: Aiello EJ,Buist DS,Wagner EH,Tuzzio L,Greene SM,Lamerato LE,Field TS,Herrinton LJ,Haque R,Hart G,Bischoff KJ,Geiger AM

    更新日期:2008-02-01 00:00:00

  • Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.

    abstract::Neurotoxicity is a common side-effect during taxane therapy. The prevalence and severity of long-term neurotoxicity following therapy is unknown. The authors conducted a cross-sectional study of 50 consecutive patients with stage I-III BC, who were within 6 months and 2 years of completing adjuvant taxane therapy and ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1278-0

    authors: Hershman DL,Weimer LH,Wang A,Kranwinkel G,Brafman L,Fuentes D,Awad D,Crew KD

    更新日期:2011-02-01 00:00:00

  • Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.

    abstract::The aim of this study was to evaluate the difference in outcomes based on p53 overexpression of patients with breast cancer who received adjuvant therapy following local treatment for invasive ductal carcinoma, not otherwise specified. We analyzed data from 4,683 patients with cancer enrolled in two institutions betwe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-009-0560-5

    authors: Kim HS,Yom CK,Kim HJ,Lee JW,Sohn JH,Kim JH,Park YL,Ahn SH

    更新日期:2010-06-01 00:00:00

  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

    abstract::Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005848921895

    authors: Tortoriello A,Facchini G,Caponigro F,Santangelo M,Benassai G,Persico G,Citarella A,Carola M,Marzano N,Iaffaioli RV

    更新日期:1998-01-01 00:00:00

  • Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature.

    abstract::Angiosarcoma of the breast (AB) is a rare entity: its overall incidence is estimated at between 0.002% and 0.005% per year. Some potential risk factors have been described, mainly previous irradiation of the breast. We report the experience of the European Institute of Oncology with this unusual disease from January 1...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9429-z

    authors: Luini A,Gatti G,Diaz J,Botteri E,Oliveira E,Cecilio Sahium de Almeida R,Veronesi P,Intra M,Pagani G,Naninato P,Viale G

    更新日期:2007-09-01 00:00:00

  • What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer?

    abstract::The epidermal growth factor receptor (EGFR) is expressed in benign and malignant breast epithelium. The EGFR, when mutated or over-expressed in the presence of its ligand, is transforming in other tissues or cell types. It is therefore of major interest in the pathogenesis of human breast cancer to understand the role...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666176

    authors: Harris AL

    更新日期:1994-01-01 00:00:00

  • Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

    abstract:PURPOSE:Androgen receptor (AR) and AR signaling pathways are thought to play a role in breast cancer (BC) and are potentially related to treatment responses and outcomes. Ankyrin 3 (ANK3) is associated with AR stability in cancer cells. In the present study, we investigated the clinicopathological utility of ANK3 expre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05216-w

    authors: Kurozumi S,Joseph C,Raafat S,Sonbul S,Kariri Y,Alsaeed S,Pigera M,Alsaleem M,Nolan CC,Johnston SJ,Aleskandarany MA,Ogden A,Fujii T,Shirabe K,Martin SG,Alshankyty I,Mongan NP,Ellis IO,Green AR,Rakha EA

    更新日期:2019-07-01 00:00:00

  • Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors.

    abstract::Elevated body weight is a risk factor for postmenopausal breast cancer and is associated with increased incidence of spontaneous and chemically induced mammary tumors (MTs) in rodents. In this study, genetically obese Lep(ob)Lep(ob) female mice that overexpress human TGF-alpha (transforming growth factor-alpha) were u...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1021891825399

    authors: Cleary MP,Phillips FC,Getzin SC,Jacobson TL,Jacobson MK,Christensen TA,Juneja SC,Grande JP,Maihle NJ

    更新日期:2003-02-01 00:00:00

  • HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

    abstract::The proto-oncogene, HER2, has prognostic and predictive relevance in invasive breast cancer (IBC). HER2 testing of primary IBC guides treatment selection and is assumed to reflect HER2 status of associated metastases, although HER2 discordance between IBC and metastasis has been reported. Systematic review and meta-an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-011-1632-x

    authors: Houssami N,Macaskill P,Balleine RL,Bilous M,Pegram MD

    更新日期:2011-10-01 00:00:00

  • Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

    abstract::Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0329-x

    authors: Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

    更新日期:2010-01-01 00:00:00